SIGA Delivers Strong Financial Results in Q4 2025 Amid Heightened Biothreat Risks

SGIA, a leading provider of smallpox antiviral treatment, has reported solid financial results for the fourth quarter of 2025. The company delivered strong revenues and continued to strengthen its position as a key player in global biosecurity efforts.

In a recent conference call, SIGA's Chief Executive Officer, Diem Nguyen, highlighted the company's commitment to supporting governments worldwide in advancing preparedness strategies for potential biological threats, including smallpox. With over 30 countries and NGOs relying on SIGA's TPOXX antiviral treatment, the company is well-positioned to rapidly deploy countermeasures at scale in the event of an outbreak.

SIGA's financial performance was driven by robust sales of both oral and IV TPOXX, with revenues totaling approximately $88 million for the year. The company also secured a significant order from a country in the Asia-Pacific region, worth $13 million. This growth reflects increasing demand for TPOXX as governments worldwide reassess their preparedness strategies and expand defense budgets.

The U.S. government remains SIGA's largest customer and partner, with the company having delivered over 26 million doses of IV TPOXX to the Strategic National Stockpile under the current BARDA contract. While this contract is nearing completion, engagement with key stakeholders at HHS and ASPR continues to be active and constructive.

Notably, SIGA's pricing and manufacturing approach has been closely aligned with U.S. government priorities. The company's commitment to domestic production of active pharmaceutical ingredients and finished drug products ensures a reliable supply chain for critical medical countermeasures.

As biothreat risks continue to rise globally, SIGA remains at the forefront of international efforts to strengthen health security. The company continues to engage with governments and stakeholders in Europe and beyond, discussing stockpiling strategies and building partnerships to address emerging threats.

With a strong track record of delivery and a proven safety profile, TPOXX has established itself as an essential tool for emergency response scenarios requiring broad distribution. As SIGA looks ahead to the challenges of 2026, its focus on preparedness, stockpiling, and strategic partnerships will continue to position it as a leader in global biosecurity efforts.